CARLSBAD, Calif., May 23, 2024
/PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a
clinical-stage biotechnology company focused on developing
next-generation precision medicines that target large opportunities
in Fibroblast Growth Factor Receptor (FGFR) biology, today
announced that company management will participate in the following
investor conferences:
- TD Cowen's 5th Annual Oncology Innovation Summit:
Insights for ASCO & EHA, May 28-29,
2024: Todd Harris, CEO of TYRA, will
participate in a fireside chat on Tuesday,
May 28, 2024, at 1:00 pm
ET.
- Jefferies Global Healthcare Conference, June 5-6,
2024: TYRA management will participate in one-on-one
meetings with investors during the conference.
- 45th Annual Goldman Sachs Global Healthcare
Conference, June 10-13, 2024:
Todd Harris, CEO of TYRA, will
present on Wednesday, June 12, 2024,
at 8:40 am ET. TYRA management
will also participate in one-on-one meetings with investors during
the conference.
A live and archived webcast of the presentations will be
available via the For Investors page on the
Investor section of the TYRA website.
About Tyra Biosciences
Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage
biotechnology company focused on developing next-generation
precision medicines that target large opportunities in FGFR
biology. The Company's in-house precision medicine platform, SNÅP,
enables rapid and precise drug design through iterative molecular
SNÅPshots that help predict genetic alterations most likely to
cause acquired resistance to existing therapies. TYRA's initial
focus is on applying its accelerated small molecule drug discovery
engine to develop therapies in targeted oncology and genetically
defined conditions. TYRA is based in Carlsbad, CA.
For more information about our science, pipeline and people,
please visit www.tyra.bio and engage with us on LinkedIn.
Contact:
Amy Conrad
aconrad@tyra.bio
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-present-at-upcoming-investor-conferences-302154687.html
SOURCE Tyra Biosciences